PlusPlus Lifesciences receives patent for multi micronutrient ‘Trimacare’

Trimacare is a supplement based on the MMN model of medication

Surbhi Gupta and Sameer Agarwal of PlusPlus Lifesciences were granted a patent from the Patent Office of the Government of India for their three-stage Multi-Micronutrient (MMN) supplement called ‘Trimacare’. This patent has allowed for a nationwide launch and distribution of the product.

Trimacare is a supplement based on the MMN model of medication. This model combines traditional nutrients such as Iron, Folic Acid, and Calcium with other essential vitamins and minerals like Iodine, Zinc, Omega-3, fatty acids, Vitamins A, B, and D, among others, that are necessary for the health of pregnant women throughout all trimesters and the child’s prenatal and long-term health.

The MMN model of medication helps promote maternal health, improve birth weight, and reduce the risk of preterm birth by providing essential nutrients to the body. MMN supplements are also effective in improving childhood survival, growth, body composition, blood pressure, and respiratory and cognitive outcomes. Moreover, they are more effective against medical anaemia compared to traditional prescriptions.

Multi-micronutrients are the building blocks of life and an essential element for pregnant women. One in 2 pregnant women in India have micronutrient deficiencies. While their diet is rich in carbohydrates, it lacks the essential elements needed for a mother’s and baby’s health and sustenance.

Trimacare is India’s most sophisticated pregnancy supplement. It is a comprehensive solution as it includes 20+ critical micronutrients such as L-Methylfolate, Iro56n, Zinc, Omega-3 and other vitamins and nutrients required for pregnancy. Furthermore, the Omega 3 source is plant-based, making Trimacare suitable for vegetarian and vegan patients.

Read Previous

Peninsular Export Company launches SAARRU, India’s first native soup

Read Next

Nutrihub unveils millet look-alike rice to boost millet consumption

Leave a Reply